Secondary Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): 30 Years Experience From a Single Center  by Nunes, E.C. et al.
S240 Poster Session I234
PREDICTORS OF THERAPY-RELATED MYELODYSPLASIA AND ACUTE MY-
ELOID LEUKEMIA (T-MDS/AML) AFTER AUTOLOGOUS HEMATOPOIETIC
CELL TRANSPLANTATION (AHCT) FOR HEMATOLOGIC MALIGNANCIES
Sun, C.-L.1, Teh, J.B.1, Tomassian, L.1, Gyorffy, J.1, Wang, S.2,
Popplewell, L.3, Krishnan, A.3, Nademanee, A.3, Forman, S.3,
Armenian, S.1, Bhatia, R.3, Bhatia, S.1 1City of Hope, Duarte, CA;
2City of Hope, Duarte, CA; 3City of Hope, Duarte, CA
Background: t-MDS/AML is the major cause of non-relapse mor-
tality after aHCT for hematologic malignancies. Independent con-
tributions by pre-aHCT therapeutic exposures and aHCT-related
factors (stem cell mobilization, conditioning) to t-MDS/AML risk
are unknown.
Methods: From 1986 to 2006, 2104 consecutive patients (median age:
49 yr) received aHCTforNHL(n5 1029),MM(n5 612), orHL (n5
463), atCity ofHope (COH). Information regarding t-MDS/AMLdi-
agnosiswasprocured frommedical records andCaliforniaCancerReg-
istry to ensure complete capture. A retrospective cohort design
described the cumulative incidence of t-MDS/AML. A nested case-
control design evaluated the role of pre-aHCT therapeutic exposures
and aHCT-related factors. Cases (t-MDS/AML post-aHCT) were
matched to controls (no t-MDS/AML post-aHCT) for primary diag-
nosis, age at aHCT, year of aHCT, and race/ethnicity.
Results: By 2008, 97 patients had developed t-MDS/AML (cumula-
tive incidence: 5.5% at 10 years [HL: 7.0%, NHL: 6.4%, MM:
2.4%]). Cohort study: multivariable analysis revealed the following
to be associated with t-MDS/AML risk: diagnosis of HL (RR 5
2.0, 95%CI, 1.2-3.5; ref grp: NHL), older age at aHCT (601 yr:
RR 5 4.7, 95%CI, 2.1-10.1; ref grp:\ 40 yr), use of PBSC (RR 5
4.7, 95%CI, 1.9-11.5; ref group: BM/BM1PBSC), and exposure
to TBI (RR 5 1.7, 95%CI, 1.0-2.9). Case-control study: multivari-
able analysis revealed pre-aHCT alkylating agent (high dose: OR
5 2.3, 95% CI, 1.2-4.3) and topoisomerase II inhibitor (high dose:
OR 5 2.1, 95% CI, 1.0-4.1), stem cell mobilization with etoposide
(OR 5 7.7, 95% CI,1.7-34.8) and conditioning with TBI (OR 5
4.0, 95% CI, 2.0-8.2) to be associated with t-MDS/AML risk.
Sub-analyses by cytogenetic abnormalities revealed pre-aHCT ex-
posure to alkylating agents (OR 5 2.7, 95%CI, 1.1-6.4) and TBI
(OR 5 4.1, 95%CI, 1.7-9.8) to be associated with increased risk of
alkylating-agent associated t-MDS/AML (5/7); and mobilization
with etoposide (OR 5 14.2, 95%CI, 1.0-192) and TBI (OR 5 9.9,
95%CI, 1.7-57) to be associated with topoisomerase inhibitor-asso-
ciated t-MDS/AML (11q23/21q22). Of the 97 t-MDS/AML pa-
tients, 76 have died (median survival: 10 months from t-MDS/
AML) by the end of 2009; overall survival was 22% at 5 years.
Conclusions:This large study with near-complete ascertainment of
cases, demonstrates the role of pre-aHCT therapeutic exposures, use
of etoposide for stem cell mobilization, and exposure to TBI to
collectively and independently increase the risk of t-MDS/AML.235
TRANSPLANT PHYSICIAN PERCEPTIONS AND PRACTICE PATTERNS
REGARDING FERTILITY PRESERVATION IN HEMATOPOIETIC-CELL
TRANSPLANT (HCT) RECIPIENTS
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HCT recipients are at risk for impaired fertility. Physician percep-
tions and practices can be a barrier to informing patients about fertility
preservation options.We conducted a survey ofHCTphysicians in the
United States to evaluate knowledge of fertility preservation and to de-
scribepracticebehaviors andbarriers to discussing fertilitypreservationwith HCT recipients of child-bearing age. Using CIBMTR email list,
1035 transplant physicians were invited by email to participate in a 29-
item web survey. Of these, 185 participants completed the survey (re-
sponse rate 18%). 69% and 31%of respondents weremale and female,
68%, 22%and 10% took care of adult, pediatric andboth adult and pe-
diatric patients, and 55% and 45% had graduated frommedical school
before and after 1990, respectively. 64% of respondents had access to
infertility specialist at their own center, 28% in another institution in
the community and 8% had no access to infertility specialist. 83% re-
spondents felt that patients were interested in learning about effects
of HCT on fertility. 80% always or often felt comfortable discussing
fertility preservation with their patients. 88% always or often discussed
the impact of HCT on fertility and 51% always or often discussed fer-
tility issueswithpatients evenwhenprognosiswaspoor.However, 48%
rarely or never provided their patientswith educationalmaterials about
fertility preservation. 30%always or often consulted and54%always or
often referred their patients to an infertility specialist. 40% were un-
aware of ASCO fertility preservation guidelines for cancer patients
and29%rarely orneverused these guidelines.Commonbarriers todis-
cussing fertility preservation with patients were: patient being too ill to
delay treatment (55%), insurance not covering fertility preservation
(35%), patients inability to afford fertility preservation (33%) and
time constraints (27%).On univariate analysis, access to infertility spe-
cialistwas associatedwithconsultationand referral practices for fertility
(Table 1). Our study highlights the variation in transplant physician
perceptions and practice behaviors regarding fertility preservation. Al-
though relatively low response rate is a limitation of our study, HCT
physicians in general are interested in discussing fertility issues with
their patients but lack educational materials. Informational materials
and guidelines on fertility preservation specifically targeted to HCT
physicians are needed.
Table 1. Characteristics of respondents who consult or refer
their patients to an infertility specialist
Always/ Rarely/
Physician Characteristics Often Sometimes Never P-value#Consult infertility specialist with questions about fertility issues
Gender
Male, N (%) 36 (31) 37 (32) 43 (37) 0.45
Female, N (%) 13 (25) 22 (42) 18 (34)
Practice type
Adult, N (%) 30 (27) 40 (35) 43 (38) 0.59
Pediatric, N (%)* 18 (34) 18 (34) 17 (32)
Access to specialist
In same institution, N (%) 39 (36) 37 (35) 31 (29) <.0001
In another institution, N (%) 10 (21) 21 (45) 16 (34)
No access, N (%) 0 0 13 (100)
Refer patients who have questions about fertility to an infertility
specialist
Gender
Male, N (%) 64 (55) 31 (27) 21 (18) 0.89
Female, N (%) 28 (53) 16 (30) 9 (17)
Practice type
Adult, N (%) 60 (53) 30 (27) 23 (20) 0.53
Pediatric, N (%)* 30 (57) 16 (30) 7 (13)
Access to specialist
In same institution, N (%) 63 (59) 32 (30) 12 (11) <.0001
In another institution, N (%) 29 (62) 12 (26) 6 (13)
No access, N (%) 0 2 (15) 11 (85)*Includes physicians who take care of both adult and pediatric patients
#Chi-square or Fisher’s test p-value, as appropriate236
SECONDARY MALIGNANCY AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT): 30 YEARS EXPERIENCE FROM A
SINGLE CENTER
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Medeiros, L.A., Oliveira, M.M., Franco, V., Pasquini, R., Zanis
Neto, J. Hospital de Clinicas Federal University of Parana, Curitiba,
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is a potentially curative modality of therapy for malignant and
non-malignant diseases. As a consequence of the improvement of
supportive measures over recent years (new antibiotics and anti-fun-
gal drugs, increasing experience of HSCT centers, identification of
better donors for unrelated transplants), a increasing number of
long term survivors is at risk for late complications. Secondary ma-
lignancies are described as important causes of late morbidity and
mortality after HSCT. The aim of this study is reporting the inci-
dence and mortality from secondary malignancies over 30 years in
a single center in Brazil.
Patients and Methods: We retrospectively analyzed through our
database 1682 patients submitted to HSCT at the BMT center
from Federal University of Parana from January 1979 to December
2009. We could identify 28 cases of secondary malignancy. Patient
characteristics are summarized in table 1.
Table 1. Patient’s Characteristics
Gender n (%)Male 19
Female 09
Conditioning
Myeloablative 26
Nonmyeloablative 02
Stem cell source
Bone marrow 26
Cord blood 02
HLA match
matched 26
mismatched 02
Diagnosis
Fanconi Anemia 14
Chronic Myeloid Leukemia 6
Myelodisplastic syndrome 2
Severe Aplastic Anemia and PNH 2
Lymphoid malignancies 2
others 2
Graft versus Host Disease
Acute 10 (35)
Chronic 20 (71)Results: Cumulative incidence of secondary malignancy after HSCT
was 2,0%60,5. From 28 cases, 14 had head and neck cancer (tongue)
(50%); 5 post transplant lymphoproliferative disorders related to EBV
(PTLD), three patients had gastrointestinal tract malignancies (esoph-
agus/stomach), three skin cancers (2 basocelular carcinomas and 1ma-
lignant melanoma), and other four cases involving respectively uterus,
lung, CNS and secondary Acute Myeloid Leukemia. With a median
follow-up of 10 years (2-21), overall survival was 72% for patients
with secondary malignancy. However, this curve does not reach a pla-
teau, meaning that those patients are still at risk for death in opposition
to patients without secondary malignancy. Median time from HSCT
to diagnosis was 6.8 years. From 28 patients, 13 (46,5%) died because
of the secondary malignancy. The remaining 15 patients are alive with
no evidence of malignancy in their last follow-up. Prevalence of
chronic graft-versus-host-disease (GVHD) in the secondary
malignancy patient population was 71%.
Conclusion: Secondarymalignancies were important causes of mor-
bidity and mortality after HSCT in our center, similarly to other re-
ports from literature. Incidence was higher among Fanconi anemia
patients with oral chronic graft versus host disease. Identification
of risk factors, prevention, early intervention and close follow up
of this complication are very important measures for long term
survivors of HSCT.237
LONG-TERM SURVIVORSHIP AFTER ALLOGENEIC HEMATOPOETIC CELL
TRANSPLANTATION: STILL ONGOING NON RELAPSE RELATED MORTAL-
ITY & MORBIDITY
Arat, M., Topcuoglu, P., Soydan, E.A., Arslan, €O, €Ozcan, M., Ilhan, O.,
Akan, H., Beksac, M., Konuk, N., Uysal, A.V., Koc, H., Gurman, G.
Ankara University Faculty of Medicine, Ankara, TurkeyAs the number of long-term survivors after allogeneic hematopoi-
etic cell transplantation (allo-HCT) continue to increase, many stud-
ies have been initiated for clinical evaluations and quality-of-life
assessment. We aimed to evaluate disease status, survival probability
and late-transplant-related complications in patients surviving 5 or
more years after allo-HCT in this retrospective single cohort study.
Between 1989 and 2005 total 484 patients underwent allo-HCT
from their HLA-identical relatives. Of 194 long term survivors,
173 (91 M/82 F) were evaluated.
Results:Median age at transplantation was 31 years (range, 14-51).
Their diagnosis was mainly (90%)AML and CML. We used mainly
MAC regimen (90%) and the patients received 52% PBSC. Median
follow-up after allo-HCT was 9.8 years (5.1-20.6 ys). The incidence
of acute and chronic GvHD was 46% and 76.3%, respectively. At
their last control, 36.9% of the patients had still findings related
with chronic GvHD. But only 10 patients (15.6%) were still using
an immunosupresive agent. Twenty-eight patients with chronic
GvHD continued inhaler treatment and was frequently hospitalized
due to non-infectious obliterative pulmonary complications. In pa-
tients with chronic GvHD89% (n5 57) had dry-eye and one patient
underwent cornea transplantation. Cataract was developed in 10 pa-
tients. We observed avascular bone necrosis in 10 patients. Autolo-
gous bone graft was replaced in one of them. Secondary
malignancy was detected in 4 patients. The frequencies of the devel-
opment of dislipidemia, hypertension and type II diabetes mellitus
were 34.7%, 20.8% and 7.5 %, respectively. The social and marital
statuses of the patients were summarized in table 1. Fifteen men
(21.2%) who married at pre- or post-transplant period had become
father to a baby after allo-HCT. The relapse of underlying disease
was detected in 26 patients (only six after 5 years). We performed
a second allo-HCT for relapse (n 5 4) or secondary malignity (n
5 1) using thesame donor. The estimated probabilities of DFS and
OS at 10 and 15 years were 82.1%63.1, 72.3%65.2 and 92.9% 6
2.18, 81.7% 66.1, respectively. In conclusion, mortality due to
transplant-related complications is decreasing in long term survi-
vors. Relapse rate is decreasing dramatically. The rise in cardiovascu-
lar complications is important. Long-term allotransplant
survivorship requires a carefull follow-up both for medical and still
ongoing social problems.
Variables N (%)cGVHD 64/109 (59%)
dry eye 57 (32.9%)
BOS/BOOP 28 (16.2%)
Osteopenia/Osteoporosis 61 (74.4%)
median BMI 25 (12-40)
Obesity (BMI>29) 32 (18.5%)
Low BW (BMI<18.5) 7 (4.02%)
mariage pretx 105 (60.9%)
mariage posttx 26 (15%)
single 39 (22.5%)
fertility 15 (8.6%)
Active working 28.9%
house wife 33.5%
retired 18%
student 2.3%
relapse <5y 20 (11.3%)
relapse >5y 6 (3.4%)238
STABLE PULMONARY FUNCTION OBSERVED OVER TIME IN RECIPIENTS
OF MYELOABLATIVE DOUBLE CORD BLOOD TRANSPLANT: A SINGLE
CENTER EXPERIENCE
Milano, F.1, Riffkin, I.1, Laura, L.1,4, Gutman, J.2, Chien, J.1,4,
Delaney, C.1,3 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Colorado, Denver, CO; 3University ofWashington, Seattle,
WA; 4University of Washington, Seattle, WA
Background: Pulmonary complications, which develop in 40% to
60% of transplant recipients, represent a major cause of morbidity
